Omeros
About Omeros PipelineInvestorsNews
Press Release
View printer-friendly version << Back
European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721
-- Patients with Thrombotic Microangiopathy Will Now Be Able to Receive Extended Treatment -

SEATTLE, April 14, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the presiding European regulatory authority has approved the company's investigational product OMS721 for compassionate use. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including atypical hemolytic uremic syndrome (aHUS). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain.

The two patients in the compassionate-use study suffer from aHUS and were enrolled in the first cohort of the Phase 2 clinical trial. Based on improvements across markers of disease activity in that cohort, the investigator requested that Omeros continue to provide OMS721 so that the patients could extend their treatments. Following regulatory approval, Omeros was pleased to release shipment of OMS721 to continue treatment of these patients.

Omeros' ongoing OMS721 Phase 2 study continues to progress through its dose-ranging phase. The second cohort of patients, which received a higher dose than the first cohort, has now completed treatment. Following a pre-planned data review by internal and external physicians, if the safety data from the second cohort are acceptable, a recommendation will be made to advance as scheduled to a third cohort at an even higher dose. This third cohort could begin dosing before the end of April.

"We are pleased to extend OMS721 treatment for patients suffering with TMAs beyond the initial planned duration of the Phase 2 study," stated Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer of Omeros. "We are excited by the progress our OMS721 Phase 2 program and look forward to its continued advancement following the second-cohort data review."

About Omeros' MASP-2 Program
Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. The complement system plays a role in the inflammatory response and becomes activated as a result of tissue damage or microbial infection. MASP-2 appears to be unique to, and required for the function of, one of the principal complement activation pathways, known as the lectin pathway. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection, and its abnormal function is associated with a wide range of autoimmune disorders. MASP-2 is generated by the liver and is then released into the circulation. Adult humans who are genetically deficient in one of the proteins that activate MASP-2 do not appear to be detrimentally affected by the deficiency. Therefore, Omeros believes that it may be possible to deliver MASP-2 antibodies systemically and OMS721, its lead MASP-2 antibody, is designed to be self-administered by subcutaneous injection.

Omeros also believes that it has identified the proteins that activate the complement system's alternative pathway in humans, which is linked to a wide range of immune-related disorders. In addition to its lectin pathway inhibitors, the Company is advancing the development of antibodies that would block activation of the alternative pathway alone or in combination with the lectin pathway.

About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the company's first drug product, Omidria (phenylephrine and ketorolac injection) 1%/0.3%, has been approved by the FDA for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is currently under review for marketing approval by the European Medicines Agency. Omeros has six clinical-stage development programs focused on: complement-related thrombotic microangiopathies; Huntington's disease, schizophrenia, and cognitive impairment; addictive and compulsive disorders; and preventing problems associated with surgical procedures. In addition, Omeros has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with Omeros' ability to obtain regulatory approval for its Marketing Authorization Application in the EU for the commercialization of Omidria, Omeros' unproven preclinical and clinical development activities, regulatory oversight, product commercialization, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2015. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/european-regulatory-authority-approves-clinical-investigators-request-for-compassionate-use-with-omeros-corporations-oms721-300065317.html

SOURCE Omeros Corporation

Erin Cox, Omeros Corporation, Investor and Media Relations, 206.676.5036, ecox@omeros.com